Novartis AG $NVS Shares Bought by Corient Private Wealth LLC

Corient Private Wealth LLC grew its stake in shares of Novartis AG (NYSE:NVS) by 4.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 479,904 shares of the company’s stock after purchasing an additional 21,364 shares during the period. Corient Private Wealth LLC’s holdings in Novartis were worth $66,203,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. J.W. Cole Advisors Inc. lifted its stake in shares of Novartis by 0.6% in the fourth quarter. J.W. Cole Advisors Inc. now owns 10,577 shares of the company’s stock valued at $1,348,000 after purchasing an additional 64 shares during the period. Roundview Capital LLC lifted its position in shares of Novartis by 2.5% during the 4th quarter. Roundview Capital LLC now owns 2,711 shares of the company’s stock valued at $374,000 after acquiring an additional 66 shares during the period. IMA Advisory Services Inc. boosted its stake in shares of Novartis by 10.9% during the 4th quarter. IMA Advisory Services Inc. now owns 710 shares of the company’s stock worth $98,000 after acquiring an additional 70 shares in the last quarter. Abundance Wealth Counselors grew its holdings in shares of Novartis by 0.4% in the 4th quarter. Abundance Wealth Counselors now owns 16,927 shares of the company’s stock worth $2,334,000 after acquiring an additional 73 shares during the period. Finally, Atlantic Edge Private Wealth Management LLC increased its stake in Novartis by 3.5% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 2,230 shares of the company’s stock valued at $307,000 after purchasing an additional 75 shares in the last quarter. 13.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NVS has been the subject of several research reports. Sanford C. Bernstein raised Novartis to a “hold” rating in a report on Thursday, March 19th. Argus upgraded Novartis from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a research report on Wednesday, March 11th. Weiss Ratings downgraded Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research note on Wednesday, April 29th. Finally, Morgan Stanley lifted their price target on Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a research note on Thursday, March 26th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $141.20.

Novartis Stock Performance

Shares of NYSE NVS opened at $147.17 on Friday. The company has a market cap of $280.82 billion, a PE ratio of 21.08, a price-to-earnings-growth ratio of 2.59 and a beta of 0.46. Novartis AG has a 12 month low of $112.34 and a 12 month high of $170.46. The company has a debt-to-equity ratio of 0.96, a current ratio of 0.85 and a quick ratio of 0.65. The company has a 50-day simple moving average of $149.10 and a 200-day simple moving average of $148.76.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Monday, April 27th. The company reported $1.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.11 by ($0.12). Novartis had a net margin of 24.87% and a return on equity of 38.82%. The firm had revenue of $13.52 billion for the quarter, compared to analysts’ expectations of $13.44 billion. During the same period in the previous year, the company posted $2.28 EPS. The business’s quarterly revenue was down .9% on a year-over-year basis. On average, equities analysts anticipate that Novartis AG will post 8.82 earnings per share for the current year.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.